Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer

被引：0
|
作者：
Eiji Takeuchi
Kensuke Kondo
Yoshio Okano
Michihiro Kunishige
Yoshihiro Kondo
Naoki Kadota
Hisanori Machida
Nobuo Hatakeyama
Keishi Naruse
Hirokazu Ogino
Hiroshi Nokihara
Tsutomu Shinohara
Yasuhiko Nishioka
机构：
[1] National Hospital Organization Kochi Hospital,Department of Clinical Investigation
[2] Tokushima University,Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences
[3] National Hospital Organization Kochi Hospital,Department of Respiratory Medicine
[4] National Hospital Organization Kochi Hospital,Department of Pathology
[5] Tokushima University,Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Early death; Early mortality factors; Immune checkpoint inhibitors; Lung cancer; Monotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3139 / 3147
页数：8
相关论文
共 50 条
  • [41] Efficacy of Immune Checkpoint Inhibitor Monotherapy for Patients With Massive Non-Small-Cell Lung Cancer
    Hakozaki, T.
    Kitadai, R.
    Kitagawa, S.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S520 - S521
  • [42] Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer
    Kubo, Toshio
    Ichihara, Eiki
    Harada, Daijiro
    Inoue, Koji
    Fujiwara, Keiichi
    Hosokawa, Sinobu
    Kishino, Daizo
    Kawai, Haruyuki
    Ochi, Nobuaki
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    RESPIRATORY INVESTIGATION, 2023, 61 (05) : 643 - 650
  • [43] Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
    Hakozaki, Taiki
    Hosomi, Yukio
    Kitadai, Rui
    Kitagawa, Shingo
    Okuma, Yusuke
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (11) : 2957 - 2966
  • [44] Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
    Taiki Hakozaki
    Yukio Hosomi
    Rui Kitadai
    Shingo Kitagawa
    Yusuke Okuma
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 2957 - 2966
  • [45] Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
    Pelizzari, G.
    Corvaja, C.
    Targato, G.
    Buriolla, S.
    Bortolot, M.
    Torresan, S.
    Fantin, A.
    De Maglio, G.
    Rossetto, C.
    Rizzato, S.
    Fasola, G.
    Follador, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1011 - S1011
  • [46] Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
    Soria, Jean-Charles
    Marabelle, Aurelien
    Brahmer, Julie R.
    Gettinger, Scott
    CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2256 - 2262
  • [47] Immune checkpoint pathways in non-small cell lung cancer
    Chae, Young Kwang
    Arya, Ayush
    Iams, Wade
    Cruz, Marcello
    Mohindra, Nisha
    Villaflor, Victoria
    Giles, Francis J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (05)
  • [48] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Hopkins, Ashley M.
    Kichenadasse, Ganessan
    Logan, Jessica M.
    Rowland, Andrew
    Sorich, Michael J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 475 - 476
  • [49] Immune Checkpoint Therapy in Non-Small Cell Lung Cancer
    Marrone, Kristen A.
    Brahmer, Julie R.
    CANCER JOURNAL, 2016, 22 (02): : 81 - 91
  • [50] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
12345